Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Published on December 19, 2024

Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm. Earlier in his career, he was an equity

Continue reading on website
Other news

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

December 19, 2024
clinical trials; (iii) whether Nurix will be able to fund its research and development activities and achieve its research and development

Darden Restaurants Reports Fiscal 2025 Second Quarter Results; Declares Quarterly Dividend; And Updates Fiscal 2025 Financial Outlook

December 19, 2024
Steak House8278The Capital Grille7064Seasons 524544Bahama Breeze4342Eddie V's3031The Capital Burger44